Biome Australia (BIO) Q2 2026 TU earnings summary

Executive summary

• Achieved record quarterly sales revenue of $6.5m in Q2 FY26, up 41% year-over-year, and rolling 12-month revenue of ~$22m.

• EBITDA reached ~$1.0m for the quarter and ~$1.48m for 1H26, marking eight consecutive quarters of positive EBITDA (excluding share-based payments).

• Strong cash generation enabled repayment of $722k into working capital facilities and a $421k increase in cash balance to $3.36m at quarter end.

Financial highlights

• Gross margin maintained above 61% for Q2 FY26.

• Cash receipts from customers were $6.2m, up 43% year-over-year.

• Net operating cash inflow of ~$1.24m, including a $657k R&D rebate.

• Inventory at quarter end was $3.9m (wholesale value $10m), up $500k from Q1.

Outlook and guidance

• Management expects continued revenue growth to increasingly flow through to earnings and cash generation.

• Focus remains on expanding international footprint and strengthening leadership in practitioner-only probiotics.